Home Cart Sign in  
Chemical Structure| 7770-78-7 Chemical Structure| 7770-78-7

Structure of Arctigenin
CAS No.: 7770-78-7

Chemical Structure| 7770-78-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Arctigenin is a naturally occuring agonist of adiponectin receptor 1 with IC50 value of 2.6μM.

Synonyms: (-)-Arctigenin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Arctigenin

CAS No. :7770-78-7
Formula : C21H24O6
M.W : 372.41
SMILES Code : COC1=C(C=C(C=C1)C[C@@H](COC2=O)[C@H]2CC3=CC(OC)=C(C=C3)O)OC
Synonyms :
(-)-Arctigenin
MDL No. :MFCD00870597
InChI Key :NQWVSMVXKMHKTF-JKSUJKDBSA-N
Pubchem ID :64981

Safety of Arctigenin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Arctigenin

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
INS-1 β cells 2.5, 5 μM 24 h ATG significantly prevented palmitate-induced INS-1 β-cell death PMC4011149
HepG2 cells 1, 5, 10 μM 24 h ATG decreased GFP protein level in a dose-dependent manner, inhibiting protein synthesis PMC4011149
HepG2 cells 5 μM 6 h ATG significantly inhibited BFA-induced XBP-1 mRNA splicing and eIF2α phosphorylation PMC4011149
HepG2 cells 5 μM 48 h ATG significantly prevented BFA-induced PARP cleavage PMC4011149
HepG2 cells 2.5, 5, 10 μM 72 h ATG inhibited BFA-induced cell death and UPR in a concentration-dependent manner PMC4011149
Murine RAW264.7 cells 100, 30, 10 μM 15 min and 3 h Reduced LPS-induced TNF-α and IL-6 production, downregulated iNOS and COX-2 expression, and decreased NO accumulation PMC8463927
Human peripheral blood mononuclear cells (PBMCs) 35.18 ± 6.01 μM Inhibited LPS-induced TNF-α production PMC8463927
Primary microglia 5 or 10 μM 12 h To investigate the effects of Arctigenin on HMGB1 or TNF-α-stimulated microglial activation and inflammatory responses. Results showed that Arctigenin significantly inhibited the increased expression of Iba-1, TNF-α, IL-1β, and iNOS induced by HMGB1 or TNF-α, and ameliorated morphological changes in microglia. PMC7589024
Podocytes 10 μM 24 h ATG improves podocyte morphology and adhesion under high glucose conditions PMC6778111
HEK293T cells 10 μM 2 h ATG binds to PP2A and enhances its activity PMC6778111

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice IMQ-induced psoriasis model Topical application 0.05 Once daily for 7 consecutive days Alleviated psoriatic skin inflammation, reduced epidermal thickening and immune cell infiltration, ameliorated splenomegaly, and decreased inflammatory cytokine levels PMC8463927
C57BL/6 mice Chronic unpredictable mild stress (CUMS)-induced depression model Oral 25, 50, or 100 mg/kg Once daily for 6 weeks To evaluate the antidepressant effects of Arctigenin on CUMS-induced depressive-like behaviors. Results demonstrated that Arctigenin significantly reduced depressive-like behaviors, inhibited microglial activation and neuroinflammatory responses, and acted through the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signaling pathways. PMC7589024
Mice Type 1 and type 2 diabetes models Oral gavage 40 mg/kg Once daily for 8 weeks ATG attenuates proteinuria and podocyte injury PMC6778111
Mice Experimental Autoimmune Encephalomyelitis (EAE) model Intraperitoneal injection 10 mg/kg Daily administration starting from the first day after EAE induction Arctigenin treatment delayed the onset of clinical symptoms in EAE mice and significantly reduced cumulative and maximum clinical scores, indicating that arctigenin alleviates clinical symptoms in EAE mice. PMC8327179
Mice SOD1G93A transgenic mice Oral 33.3 mg/kg Once daily for 6 weeks A-1 treatment improved motor performance in SOD1G93A mice, reduced skeletal muscle atrophy and fibrosis, mitigated the loss of spinal motor neurons, and decreased glial activation. Additionally, A-1 treatment improved mitochondrial function, as evidenced by elevated ATP levels and increased expression of key mitochondrial-related proteins. The A-1 treatment group also showed decreased levels of IL-1β, pIκBα/IκBα, and pNF-κB/NF-κB. PMC11176200
Female Balb/c mice Concanavalin A-induced autoimmune hepatitis model Intragastric 2.5, 5, and 10 mg/kg Twice per day for 10 days Arctigenin pretreatment significantly alleviated the liver injury, as evidenced by biochemical and histopathological investigations, whose protective effects were comparable with Prednisone acetate and Cyclosporin A. PMC6109684

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.43mL

2.69mL

1.34mL

26.85mL

5.37mL

2.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Cho MK, Park JW, et al. Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol. 2002 Jan;2(1):105-16.

[2]Sun Y, Zang Z, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One. 2013 May 14;8(5):e63354.

[3]Jang YP, Kim SR, et al. Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. J Neurosci Res. 2002 Apr 15;68(2):233-40.

[4]He B, Zhang HJ, et al. Pharmacokinetics of Arctigenin and Fructus Arctii Powder in Piglets. Front Vet Sci. 2019 Jul 25;6:235.

[5]Wang P, Solorzano W, et al. Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp. 2017 Jun;13:1-11.

[6]Yang J, Yin HS, et al. Arctigenin Attenuates Ischemia/Reperfusion Induced Ventricular Arrhythmias by Decreasing Oxidative Stress in Rats. Cell Physiol Biochem. 2018;49(2):728-742.

[7]Tan YJ, Ren YS, et al. 28-Day Oral Chronic Toxicity Study of Arctigenin in Rats. Front Pharmacol. 2018 Sep 26;9:1077.

[8]Cho MK, Park JW, Jang YP, Kim YC, Kim SG. Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol. 2002 Jan;2(1):105-16. doi: 10.1016/s1567-5769(01)00153-9. PMID: 11789661.

[9]Sun Y, Zang Z, Zhong L, Wu M, Su Q, Gao X, Zan W, Lin D, Zhao Y, Zhang Z. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One. 2013 May 14;8(5):e63354. doi: 10.1371/journal.pone.0063354. PMID: 23691032; PMCID: PMC3653934.

[10]Jang YP, Kim SR, Choi YH, Kim J, Kim SG, Markelonis GJ, Oh TH, Kim YC. Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. J Neurosci Res. 2002 Apr 15;68(2):233-40. doi: 10.1002/jnr.10204. PMID: 11948668.

 

Historical Records

Categories